AstraZeneca has not found any evidence that its COVID-19 vaccine increases the risk of blood clots, causing many countries to stop their rollout of the shot.
British drugmakers tried to calm safety concerns after the emergence of blood clots in some people, which prompted a dozen countries to stop using all or some of their supplements.
AstraZeneca, in a review of safety data from more than 17 million people who have received jobs in the UK and the European Union, found no evidence of high risk for pulmonary embolism or deep vein thrombosis, a condition associated with blood clots, the company said Sunday statement.
According to AstraZeneca, there were no signs of high risk for thrombocytopenia or a low count of blood platelets.
“About 17 million people in the European Union and the UK have now received our vaccine, and the reported number of blood clots in this group is less than the hundreds of cases that would be expected among the general public,” said AstraZeneca. chief Medical Officer.
“The nature of the epidemic has attracted attention in individual cases and we are going beyond standard practices for the safety monitoring of licensed drugs in reporting vaccine incidents to ensure public safety.”
AstraZeneca’s statement stated by the World Health Organization that countries should continue to use the “excellent” vaccine among blood clots.
Health officials have said there is no indication that blood clots from seven countries – including Ireland, Thailand and the Netherlands – have caused the jab – to suspend or push back their distribution of AstraZeneca vaccines.
Italy, Austria and four other European countries have stopped using the dose from some batches of the vaccine, while health officials have investigated concerns.
AstraZeneca said it knew of 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism among people vaccinated in the European Union and the UK, a number “occurring naturally in a general population of this size Much less than it would be. “
“The company is holding the issue under close review but the available evidence does not confirm that the vaccine is the cause,” said AstraZeneca. “To overcome the epidemic, it is important that people are vaccinated to do so.”
The company stated that there are no quality problems with any batch of AstraZeneca vaccines.
US-listed shares of AstraZeneca were flat on prepaid trading at $ 48.44 on Monday until around 7:17 p.m.
With post wires
Leave a Reply